针对不同种族的局部细胞癌的结果
Wei Zheng So1, Khi Yung Fong2, Ziting Wang3
1National University of Singapore, Singapore soweizhengs@gmail.com.
Clinical medicine & research
|November 20, 2023
概括
这项关于新加坡细胞癌 (RCC) 的研究发现了诊断,手术方法和结果的种族差异. 马来人和印度患者的并发症率和复发率较高,突出显示了对量身定制护理的需要.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 细胞癌 (RCC) 的流行病学数据有限.
- 了解RCC结果的种族差异对于有针对性的医疗保健至关重要.
- 新加坡的多民族人口为此类研究提供了独特的环境.
研究的目的:
- 为了比较新加坡不同种族的RCC患者的手术前,手术和瘤结果.
- 为了确定在RCC.部分切除术的管理和结果中的种族差异.
- 评估外科手术技术 (拉巴镜与机器人) 对基于种族的结果的影响.
主要方法:
- 对137名经过部分切除术的RCC患者 (2009-2020) 的回顾性队列分析.
- 统计分析包括千平方测试,ANOVA和Kaplan-Meier生存估计.
- 在各族群 (中国人,马来人,印度人和其他人) 中对手术前特征,手术结果和瘤结果进行比较.
主要成果:
- 印度患者在年轻时被诊断出来. 马来人和印度患者的手术内转换率更高,手术后停留时间更长.
- 马来人患者不太可能接受机器人手术,并且转移性复发率最高 (10.5%).
- 在采用外科手术方法和术后康复方面观察到显著的种族差异.
结论:
- 在新加坡,细胞癌的呈现,手术管理和瘤结果存在种族差异.
- 马来人和印度人面临着不同的挑战,包括更高的并发症率和复发率.
- 需要进一步的研究和文化敏感的方法来解决RCC护理中的这些差异.
更多相关视频
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.6K
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.6K
相关概念视频
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
01:21Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356